ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1119

Comparison High Intensity Laser Therapy and Wrist Splint in the Treatment of Lateral Epicondylitis

Ekrem Akkurt1, Halim Yilmaz2, Ali Salli3, Selman Parlak4, Gulten Karaca5 and Sami Kucuksen6, 1The Department of Physical Medicine and Rehabilitation, Konya Education and Research Hospital, Konya, Turkey, MD, Konya, Turkey, 2The Department of Physical Medicine and Rehabilitation, Konya Education and Research Hospital, MD, Konya, Turkey, 3The Department of Physical Medicine and Rehabilitation, Necmettin Erbakan University, Meram Faculty of Medicine, MD, KONYA, Turkey, 4MD, konya, Turkey, 51The Department of Physical Medicine and Rehabilitation, Konya Education and Research Hospital, Konya, Turkey, MD, Konya, Turkey, 6MD, kONYA, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Tendonitis/bursitis

  • Tweet
  • Email
  • Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Clinical Focus

Session Type: Abstract Submissions (ACR)

Background/Purpose: Lateral epicondylitis (LA), also known as tennis elbow, is a quite common disease with a prevalence of 1.7% and mostly seen between 3rd and 6th decade of life.

Methods:

67 elbows diagnosed with lateral epicondylitis were divided randomly into two groups as HILT (33,9  and as wrist splint (34). 33 wrists were treated for 5 sessions weekly for two weeks.  The remaining elbows, 34, were recommended to wear wrist splints for 6 subsequent weeks. The aim of this study is to compare the efficacy of HILT and wrist splint treatment. Patients were evaluated before and in 6th week of post treatment period using visual analogue scale for pain (VAS) during activity and resting, Disabilities of the Arm, Shoulder and Hand (DASH) Score, hand grip strength test (HGST), and Short Form 36 (SF-36).

Results:

Out of the 60 patients, 14 male and 46 female with a mean age of 46,28 ± 9,44. The pretreatment and 6th week scores of the HILT patients were as follows: VAS activity 8,33±1,97, 6,03±2.35 VAS resting 5,75±3,27, 2,72±2.41, DASH 53.40±22, 38.33±17.10, HGST 15.49±9.95, 21,52±13,18, SF 36 physical component 35.35±17,72, 66,74±15,75, and SF 36 mental component 46,43±17.31, 62,16±17,93 and of the wrist splint group as the following: VAS activity 7,77±2,34, 6,14±3,20, VAS resting 4,67±3,10, 2,79±3.01 ,  DASH 44,68±16,03, 30.49±17.52, HGST 17,19±7,66 , 20,81±8,11,  SF 36 physical component 36,70±15,13, 50,42±18,93, and SF 36 mental component 38,62±15,57, 52,33±18,72.

The VAS activity, resting, DASH, HGST, SF36 physical, and SF36 mental component scores of both groups revealed significant improvements on comparing their pretreatment and 6th week score. Except the SF physical component scores, none of these variables were statistically significant when the HILT and wrist splint groups were compared. The statistical difference was in favor of the HILT group.

Conclusion:

The findings of the present study suggest that both HILT and wrist splints are reliable, safe, and effective treatment options in LE patients. Although HILT has been determined to be more effective in increasing functional capacity, both groups revealed almost equally positive outcomes, in the short and long term considering pain, functional status and quality of life.


Disclosure:

E. Akkurt,
None;

H. Yilmaz,
None;

A. Salli,
None;

S. Parlak,
None;

G. Karaca,
None;

S. Kucuksen,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-high-intensity-laser-therapy-and-wrist-splint-in-the-treatment-of-lateral-epicondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology